Biotechnology
Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented at the 2023 American Academy of Dermatology Annual Meeting
* At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), including 33% achieving HiSCR100. * Safety results were consistent with previous trials of izokibep and the IL-17Ai class, with no increased risk of infection, including candida. SAN DIEGO ,SHANGHAI and SY...
2023-03-20 08:41
2184
AMGEN AND NSG BIOLABS ANNOUNCE ALBATROZ THERAPEUTICS AS WINNER OF FIRST AMGEN GOLDEN TICKET IN SINGAPORE
The Golden Ticket will help to boost the biotech startup's capabilities and to develop further the emerging biotech ecosystem inSoutheast Asia SINGAPORE, March 20, 2023 /PRNewswire/ -- Leading global biotechnology company Amgen and NSG BioLabs,Singapore's largest and leading provider of biotechn...
2023-03-20 08:00
1907
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...
2023-03-17 04:30
2286
Angel Yeast Showcases Latest Product Innovations at Food Ingredients China 2023
SHANGHAI, March 16, 2023 /PRNewswire/ -- Angel Yeast
2023-03-16 20:16
3525
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...
2023-03-16 09:58
2145
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD
* Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. * Calibr will continue to collaborate in the development of AK0705. * The collaboration is an extension of the current co-development collaboration. SHANGHAI, March 16, 2...
2023-03-16 07:50
2983
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
SHANGHAI, March 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the full year endedDecember 31, 20...
2023-03-15 20:45
1954
Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023
* Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-targeting programs HMBD-001 (HER3 mAb) and HMBD-501 (HER3 ADC) * HMBD-001 used as monotherapy or in combination with cetuximab effectively inhibits tumor growth in preclinical squamous cell carcino...
2023-03-15 18:30
2170
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023
SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as Late-Breaking Research in 114th Annual Meeting of the American Association for Cancer Research (AACR 2023). The res...
2023-03-15 10:06
2336
Illumina launches its first product enabling long- and short-read sequencing on one instrument
Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO, March 15, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced th...
2023-03-15 08:00
2114
YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION
* Business Combination to deliver approximately $36 million of gross proceeds * YS Biopharma expects to close the Business Combination on March 16, 2023 * YS Biopharma Ordinary Shares and YS Biopharma Warrants expected to begin trading on the Nasdaq onMarch 17, 2023 under the symbols "YS" and...
2023-03-15 04:01
3686
Ajinomoto Bio-Pharma Services Awarded Three 'CDMO Leadership Awards'
SAN DIEGO and TOKYO and WETTEREN, Belgium, March 14, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility,...
2023-03-14 20:05
1617
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China
- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. - The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in pat...
2023-03-14 12:29
2311
Qritive and Corista Announce Partnership to Advance the Use of Computational Digital Pathology Workflows with Integrated Image Management
SINGAPORE, March 14, 2023 /PRNewswire/ -- Qritive, a leading developer of artificial intelligence (AI)-powered cancer diagnostics, and, Corista, a leading provider of clinical, research and educational digital pathology image management solutions, are announcing a new partnership in digital patho...
2023-03-14 08:01
2444
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
MELBOURNE, Australia, March 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...
2023-03-14 05:11
1632
Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company
SHANGHAI, March 13, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, would like to announce that it considers its...
2023-03-13 07:51
2469
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
ZUG, Switzerland, March 9, 2023 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc.
2023-03-09 20:01
2154
GRAND LAUNCHING OF DNATEST.ID, A COMPREHENSIVE DNA TEST IN INDONESIA
JAKARTA, Indonesia, March 9, 2023 /PRNewswire/ -- PT Henindo Technologies Citra Mulia (HENINDO) together with PT Regene Artifisial Inteligen (REGENE) announce the launching of a comprehensive DNA TEST under the brand name of DNAtest.id. The event was attended byProf. Dr. Amien Soebandrio, PhD, Sp...
2023-03-09 10:00
2391
DIGITAL THERAPEUTICS STARTUP RESPIREE™ GAINS US FDA CLEARANCE FOR ITS RS001 CARDIO-RESPIRATORY WEARABLE
SINGAPORE, March 9, 2023 /PRNewswire/ -- Digital therapeutics startup Respiree
2023-03-09 08:14
5503
Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)
– CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD – DUBLIN, March 9, 2023 /PRNewswire/ -- Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, tod...
2023-03-09 05:00
1944
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 256 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2938
